Test Your Knowledge

A. Reduced rate of LDL receptor degradation B. Adenosine triphosphate-citrate lyase (ACL) inhibitio C. Decreased cholesterol synthesis D. Decreased absorption of dietary cholesterol

A. May be used routinely in pregnant women with hypercholesterolemia B. In pregnant women who develop preeclampsia C. In pregnant women with familial hypercholesterolemia D. Should never be used during pregnancy due to teratogenic risk

A. New-onset type 2 diabetes B. Pancreatitis C. Muscle toxicity D. Bempedoic acid does not increase the risk of serious adverse events when added to statins

A. Greater decrease in low-density lipoprotein cholesterol (LDL-C) levels B. Similar reduction in the risk of major adverse cardiovascular events C. Greater reduction in triglyceride levels D. Higher incidence of muscle toxicity

Featured

What’s new in the 2025 ESC/EAS Guideline Update for Dyslipidaemia Management

The 2025 Focused Update of the 2019 European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS) Guidelines for the management of dyslipidaemias reviewed the latest evidence and provided new recommendations based on compelling and practice-changing evidence.

Test Your Knowledge

Featured

What’s new in the 2025 ESC/EAS Guideline Update for Dyslipidaemia Management

Your Privacy